Onesource Specialty Pharma Limited has informed the Exchange about General Update on Composite Scheme of Amalgamation (Merger by Absorption) amongst SteriscienceSpecialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides PharmaServices Private Limited and Onesource Specialty Pharma Limited and their respective shareholders -
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Onesource Specialty Pharma reviewed the proposed composite scheme of amalgamation involving Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource itself. The scheme aims to bring Steriscience's facilities in Poland and Baroda into the listed entity OneSource, and the company has already received in-principle approval from the stock exchanges (BSE and NSE). However, on March 6, 2026, the Board decided to undertake an additional review before filing the application with the National Company Law Tribunal (NCLT). This review will be completed within the six-month approval window granted by the stock exchanges. No swap ratio or final scheme details have been disclosed in this update.
The merger is delayed but not cancelled — the Board is opting for more due diligence before the NCLT step, which may create short-term uncertainty for shareholders awaiting clarity on the share swap ratio and deal structure.